Literature DB >> 35349786

The 13th International Oncolytic Virus Conference: Powerful payloads gain clinical momentum.

Shruthi Naik1, Luke Russell2.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35349786      PMCID： PMC9077475          DOI： 10.1016/j.ymthe.2022.03.010

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   12.910


× No keyword cloud information.
  5 in total

1.  First oncolytic virus approved for melanoma immunotherapy.

Authors:  Jonathan Pol; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

2.  Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.

Authors:  Joselle Cook; Kah-Whye Peng; Thomas E Witzig; Stephen M Broski; Jose C Villasboas; Jonas Paludo; Mrinal Patnaik; Vincent Rajkumar; Angela Dispenzieri; Nelson Leung; Francis Buadi; Nora Bennani; Stephen M Ansell; Lianwen Zhang; Nandakumar Packiriswamy; Baskar Balakrishnan; Bethany Brunton; Marissa Giers; Brenda Ginos; Amylou C Dueck; Susan Geyer; Morie A Gertz; Rahma Warsame; Ronald S Go; Suzanne R Hayman; David Dingli; Shaji Kumar; Leif Bergsagel; Javier L Munoz; Wilson Gonsalves; Taxiarchis Kourelis; Eli Muchtar; Prashant Kapoor; Robert A Kyle; Yi Lin; Mustaqeem Siddiqui; Amie Fonder; Miriam Hobbs; Lisa Hwa; Shruthi Naik; Stephen J Russell; Martha Q Lacy
Journal:  Blood Adv       Date:  2022-06-14

Review 3.  Oncolytic Virotherapy with Myxoma Virus.

Authors:  Masmudur M Rahman; Grant McFadden
Journal:  J Clin Med       Date:  2020-01-08       Impact factor: 4.241

Review 4.  Oncolytic Viruses and the Immune System: The Dynamic Duo.

Authors:  Ana Lemos de Matos; Lina S Franco; Grant McFadden
Journal:  Mol Ther Methods Clin Dev       Date:  2020-01-15       Impact factor: 6.698

Review 5.  Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer.

Authors:  Sara A Collins; Ashish H Shah; Derek Ostertag; Noriyuki Kasahara; Douglas J Jolly
Journal:  Expert Opin Biol Ther       Date:  2021-05-06       Impact factor: 5.589
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.